What is the Share Price of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd share price is ₹335.05 As on 09 May, 2025|14:40

Home
>
Stocks
>
Samrat Pharmachem Ltd

Samrat Pharmachem Ltd Share Price

Q: What is the Market Cap of Samrat Pharmachem Ltd?

The Market Cap of Samrat Pharmachem Ltd is ₹105 As on 09 May, 2025|14:40

Q: What is PE Ratio of Samrat Pharmachem Ltd?

The P/E ratio of Samrat Pharmachem Ltd is 11.7 As on 09 May, 2025|14:40

Q: What is PB Ratio of Samrat Pharmachem Ltd?

The PB ratio of Samrat Pharmachem Ltd is 1.49 As on 09 May, 2025|14:40

₹ 0.00 0 (0%)
Updated on 01-01-1970 5:30 AM

Stock Rating

BSE

Pros 3

Cons 7

Samrat Pharmachem Ltd Price Performance

Day's Low
₹0

Day's High
₹0

₹ 0

52-w low
₹0

52-w high
₹0

Day's open
₹0
Previous close
₹0
VWAP
₹0
Lower price band
₹0
Upper price band
₹0

Today's Market Action

Its last traded stock price on BSE was 335.05 down by -1.05%. The total volume of shares on NSE and BSE combined was 1,323 shares. Its total combined turnover was Rs 0.04 crores.

Samrat Pharmachem Ltd Medium and Long Term Market Action

The stock price of Samrat Pharmachem Ltd is down by -100% over the last one month. Don't forget to check the full stock price history in the table below.

Samrat Pharmachem Ltd Fundamentals

Market Cap (Cr): 105
Book Value (₹):
Stock P/E:
Revenue (Cr):
Total Debt (Cr):

Face Value (₹):
Roce (%):
ROE (%):
Earnings (Cr):
Promoter’s Holdings (%):

EPS (₹):
Debt to Equity:
Dividend Yield (%):
Cash (Cr):

Samrat Pharmachem Ltd Mutual fund holdings and trends

FUND NAME	Quantity	Monthly Change (Qty)

Samrat Pharmachem Ltd Shareholding Pattern

Similar Stocks

Company	Price	Market Cap (Cr)	P/E

About Samrat Pharmachem Ltd

Data not available.

Samrat Pharmachem Ltd FAQ's

What is Share Price of Samrat Pharmachem Ltd?

What is the Market Cap of Samrat Pharmachem Ltd?

What is PE Ratio of Samrat Pharmachem Ltd?

What is PB Ratio of Samrat Pharmachem Ltd?

What is the CAGR of Samrat Pharmachem Ltd?

How to Buy Samrat Pharmachem Ltd Share?

Can I buy Samrat Pharmachem Ltd from Samco?

How do I buy Samrat Pharmachem Ltd from Samco?

Financials

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Net Profit)

Standalone Financial Performace In Graph(Net Profit)

(*All values are in Rs. Cr)

Consolidated Financial Performace In Graph(Cash Flow)

Standalone Financial Performace In Graph(Cash Flow)

News

Review

Pros

Above Average Sustainable RoE
The company generates a sustainable return on equity greater than the expected cost of capital which implies that the underlying business can create and compound value over a period time due to it's ability to generate above average return on capital.
Great Cash Conversion of Profits
The business has a great cash conversion ratio since it is able to convert a signifant portion of operating earnings of 180.00% into operating cash flow. This implies a great working capital cycle and large cash flows for either funding growth or dividends. This shall positively impact shareholder returns.
Asset Light Business
The company operates a great asset light business with a high Asset turnover ratio of 24.36. A high asset turnover ratio is a great driver of RoE and can improve shareholder returns. A relatively higher asset turnover ratio also will result in lower dilution as the business grows its revenues as earnings.

Cons

Low Return on Capital Employed
The company is unable to generate sufficient return on capital employed which impairs it's ability to generate high return for shareholders after accounting for taxes, interest and other non-equity stakeholders.
Low Interest Coverage
The company has a very low Interest coverage ratio of 2.00 times which implies that a large portion of operating profits are getting attributed to payment of interest to debtholders. This leaves lower earnings and cash flows for equity shareholders which is negative for returns.
Highly Cyclical Industry
The company operates an extremely cyclical business with unpredictable earnings and cash flows. This shall result in very high stock price volatility and returns which would negatively impact shareholder returns.
Low Pricing Power & High Competition
The business has extremely low pricing power and is vulnerable to competitive pressure which can significantly impact shareholder returns.
Poor Capital Allocation
The company has disproportionately high amount of assets locked up in working capital, cash and cash equivalents, loans and advances, etc to the extent of 88.52 % of total assets. This reflects poorly on the capital allocation strategy of the management which negatively impacts shareholder returns.
Poor Working Capital Cycle
The company has a very poor working capital cycle of 123 days which requires very high investments in working capital. This reduces free cash flow generation for the business and negatively impacts shareholder value and returns.
Poor Corporate Governance
The general corporate governance standards of the company are poor which can negatively impact shareholder value and returns.

Valuation Analysis

Margin of safety
(09/05/2025)

105

Margin of Safety Index: High

100.00%

100.00% People are bullish about Samrat Pharmachem Ltd

0.00%

0.00 % People are bearish about Samrat Pharmachem Ltd

What is your opinion about this Stock?

Historical Data

Date	Open	High	Low	Close	Volume	Daily Change %